ArticleInterdisciplinary cardiovascular and thoracic surgery2026
Transcatheter Valve Replacement in Carcinoid Heart Disease: A Potential Change of Paradigm.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Carcinoid Heart Disease: Surgical Timing, Right Ventricular Risk Stratification and Operative Strategy.Journal of cardiovascular development and disease · 2026Review
- Article
- A case report of acute carcinoid heart failure during lutetium-177 dotatate-triapine treatment for well-differentiated neuroendocrine tumors.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the feasibility and early clinical outcomes of transcatheter valve replacement in high-surgical-risk patients with carcinoid heart disease. MATERIALS AND
methodsThis study included 15 procedures performed in 9 patients with symptomatic carcinoid heart disease between 2021 and 2025. Valve involvement included the pulmonary valve in 9 cases, the tricuspid valve in 5 cases, and the aortic valve in 1 case. Valve selection (SAPIEN 3, TOPAZ, LUX) was individualized according to anatomical considerations. All 9 patients received intravenous periprocedural octreotide. Outcomes included procedural success, NYHA class, and echocardiographic evaluation of valve and ventricular function.
resultsSingle-valve replacement was performed in 4 patients (2 pulmonary and 2 tricuspid). Double-valve replacement involving the pulmonary and tricuspid valves was performed in 4 patients, and 1 patient underwent triple-valve replacement (aortic, pulmonary, and tricuspid). One high-risk patient required conversion after a tricuspid procedure but ultimately recovered after a prolonged hospital stay. At a median follow-up of 9.9 months (IQR 3.5), all patients showed clinical improvement. One patient developed a transient tricuspid paravalvular thrombus without dysfunction or clinical consequence. Echocardiography demonstrated a reduction in right ventricular diameter. No case of endocarditis was observed. One patient died 4 months post-procedure from tumour progression.
conclusionsThis first series of transcatheter valve replacements in carcinoid heart disease suggests that a complete percutaneous approach is feasible, safe, and potentially beneficial. These early results warrant confirmation in larger cohorts with longer follow-up and may represent a paradigm shift in the management of carcinoid valve disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.